17 results about "Fexofenadine" patented technology

To provide a pharmaceutical composition having excellent anti-inflammatory action.SOLUTION: A pharmaceutical composition contains (a) fexofenadine or salt thereof; (b) glycyrrhizinic acid or a salt thereof, or belladonna or extract thereof; and (c) one or more selected from ephedrine or a derivative thereof or a salt thereof, phenylephrine or a salt thereof, and caffeine.SELECTED DRAWING: None

To provide a pharmaceutical composition having excellent anti-inflammatory action.SOLUTION: A pharmaceutical composition contains (a) fexofenadine or salt thereof; (b) tranexamic acid or salt thereof; and (c) one or more selected from ephedrine or a derivative thereof or a salt thereof, and caffeine.SELECTED DRAWING: None

The present invention relates to a composition for preventing, ameliorating or treating neurodegenerative diseases comprising fexofenadine. Fexofenadine is a compound which has been popularized for pharmaceutical use, the safety of fexofenadine has been proved, and when fexofenadine is administered to a neurodegenerative disease model, it is confirmed that the behavioral ability is significantly improved, and the fexofenadine has an effect of protecting nerve cells. The present invention has the effect of inhibiting, for example, the death of dopaminergic neurons, the inflammation-mediated damage of nerve cells or the degradation of nerve cells, the formation of alpha-synuclein aggregates, the abnormal increase in the number of astrocytes or the activation of astrocytes, and the like, and also has the effect of prolonging the life of a neurodegenerative disease model. Therefore, the composition according to the present invention can be effectively used for preventing, ameliorating or treating neurodegenerative diseases.

The present invention relates to a process for the preparation of highly pure enantiomer of Fezolinetant, and in particular highly pure (R)-Fezolinetant. The invention also relates to chiral resolution by acid for the preparation of highly pure R-Fezolinetant. Additionally, the invention relates to a process for preparing intermediates useful for the preparation of (R)-Fezolinetant, their uses and a process for preparing (R)-Fezolinetant.

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The present disclosure is directed to a process for preparing a spray dried formulation comprising fexofenadine zwitterion dihydrate, comprising spray drying (i) a fexofenadine zwitterion dihydrate composition, and (ii) an inert matrix. The present disclosure also provides products prepared according to the processes described herein, spray dried formulations comprising fexofenadine zwitterion dihydrate and an inert matrix, oral solid dosage forms comprising the spray dried formulations described herein, and a method for alleviating allergy symptoms in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a spray dried formulation or oral solid dosage form described herein.

The present invention discloses a pharmaceutical composition with a synergistic analgesic effect and its application. The pharmaceutical composition is composed of drug A and drug B; drug A is one or more of Kv7 potassium channel openers, and drug B is one or more of antihistamine drugs. Drug A is a Kv7 potassium channel opener such as retigabine, flupirtine or a pharmaceutically acceptable salt or solvate thereof, and drug B is an antihistamine drug such as promethazine and / or fexofenadine or a pharmaceutically acceptable salt or solvate thereof. By evaluating the "gold standard" for drug interaction - the isobolographic analysis method, the present invention proves in visceral pain, inflammatory pain and neuropathic pain models that the three drug combinations of flupirtine - promethazine, flupirtine - fexofenadine and retigabine - promethazine can produce a synergistic analgesic effect, with a strong and lasting analgesic effect, and can avoid or reduce drug toxic and side effects, having good application prospects and providing a new strategy for effective clinical analgesia.

Fexofenadine zwitterionic dihydrate form I of formula (I) Paraben-free aqueous pharmaceutical suspension formulations and uses thereof are provided, including JPEG2026501487000031.jpg4390. In certain embodiments, the formulations include polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.

This disclosure is also based on the discovery that it is possible to eliminate the sweetener from a fexofenadine zwitterion dihydrate suspension and still achieve satisfactory taste masking by including the sweetener solely in the external phase. In addition, this disclosure is based on the discovery that it is possible to use an inert matrix containing only mannitol when turning suspensions of fexofenadine zwitterion dihydrate into granules. Accordingly, this disclosure is directed to sugar-free chewable fexofenadine tablets comprising sprayed and dried fexofenadine granules comprising a mannitol matrix and a composition devoid of a sweetener, said composition comprising fexofenadine zwitterion dihydrate, a wetting agent, a binder, an alkalizing agent, and a buffer; and an external phase comprising a flavoring agent, a disintegrant, the wetting agent, a diluent, a sweetener, and one or more lubricant. The disclosure also includes methods of making these tablets. In one embodiment, the method of producing a sugar- free chewable fexofenadine tablet includes: generating fexofenadine granules by spraying and drying a liquid fexofenadine suspension devoid of a sweetener comprising fexofenadine zwitterion dihydrate, a wetting agent, a binder, an alkalizing agent, and a buffer onto a mannitol matrix; and compressing the fexofenadine granules with an external phase comprising a flavoring agent, a disintegrant, the wetting agent, a diluent, a sweetener, one or more lubricant.

Provided is a paraben-free aqueous pharmaceutical suspension formulation comprising fexofenadine zwitterionic dihydrate Form I of formula (I)and uses thereof. In certain embodiments, the formulation comprises polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.

To provide a pharmaceutical composition having excellent anti-inflammatory action.SOLUTION: A pharmaceutical composition contains (a) fexofenadine or salt thereof; (b) glycyrrhizinic acid or a salt thereof, or belladonna or extract thereof; and (c) one or more selected from ephedrine or a derivative thereof or a salt thereof, phenylephrine or a salt thereof, and caffeine.SELECTED DRAWING: None

The present invention provides a semi-solid composition comprising a gel component in an amount sufficient to provide a gel product with binding force, an antihistamine composition comprising an antihistamine agent, and a complexing agent wherein the complexing agent is capable of interacting with the antihistamine agent and forming an antihistamine complex. In one embodiment, the antihistamine agent includes diphenhydramine, cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, azelastine, bilastine, rupatadine, or a derivative, a salt, or a combination thereof.

The application discloses a preparation method of fexofenadine isomer, and the fexofenadine isomer is synthesized from 2-indanone and diphenylpiperidinemethanol through eight steps; the preparation method is high in operability, reasonable in process design, and can realize industrial production; the reagents used in the synthesis method are simple and easy to obtain; and the prepared fexofenadine isomer has a purity of more than 98.5%.

The present invention relates to a composition for prevention, alleviation, or treatment of neurodegenerative diseases, comprising fexofenadine. Fexofenadine, a compound already commercialized for pharmacological purposes, has proven to be safe, demonstrated significant improvements in behavioral abilities when administered to a neurodegenerative disease model, and exhibits neuroprotective effects of inhibiting the death of dopaminergic neurons, reducing damage to inflammation-mediated neurons or neuronal degeneration, preventing the formation of α-synuclein aggregates, and suppressing the abnormal increase and activation of astrocytes, and has the effect of extending the lifespan in the degenerative neurological disease model. Thus, the composition according to the present invention can be advantageously used for preventing, alleviating, or treating neurodegenerative diseases.

The invention belongs to the technical field of medicines, and particularly relates to an ebastine orally disintegrating tablet and a preparation method thereof. According to the ebastine orally disintegrating tablet, the microcrystalline cellulose and the mannitol are used as filling agents at the same time, the average particle size of the microcrystalline cellulose and the mannitol is controlled, the problem that in the prior art, the ebastine orally disintegrating tablet is poor in dissolution performance is solved, and the ebastine orally disintegrating tablet has good disintegration performance. The ebastine orally disintegrating tablet disclosed by the invention is obtained by firstly granulating through a fluidized bed and then tabletting, the tabletting is smooth and not astringent in the pressing process and has better compressibility, the fluidized bed granulating process is simple and easy to operate and control, the equipment is easy to obtain, the production cost is lower, and the ebastine orally disintegrating tablet is suitable for large-scale production.

Provided is a paraben-free aqueous pharmaceutical suspension formulation comprising fexofenadine zwitterionic dihydrate Form I of formula (I) and uses thereof. In certain embodiments, the formulation comprises polypropylene glycol, edetate disodium, potassium sorbate, xanthan gum, poloxamer 407, titanium dioxide, sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate, artificial raspberry cream flavor, sucrose, xylitol, and purified water. The disclosure also includes methods of making such formulations.